OpenAI acquires drug development platform Orchestra Bio and integrates it into the Rosalind life sciences system
OpenAI acquires Orchestra Bio
AI BriefingOpenAI announces the acquisition of Orchestra Bio, a platform that helps biopharmaceutical teams coordinate the complex processes involved in drug development. Its team and technology will be integrated with Rosalind. Orchestra's agents can help teams track research and project progress, analyze the impact of events such as failed production batches on clinical trial timelines, and propose responses. The article also mentions collaborations with Novo Nordisk and Moderna, as well as the background that new drug development takes an average of 10 to 15 years.
Reported by 6 additional sources
- OpenAI acquires Orchestra Bio and will integrate it into the life sciences platform Rosalind to develop pharmaceutical agentsThe Decoder:AI News · 26 days ago
- OpenAI Acquires Orchestra Bio to Accelerate Drug Development CollaborationGreg Brockman · 26 days ago
- OpenAI Acquires AI Biotech Startup Orchestra BioTechCrunch:AI · 27 days ago
- OpenAI Acquires Orchestra Bio to Pursue AI-Assisted Drug DiscoveryMark Chen · 27 days ago
- OpenAI Acquires Orchestra Bio, Whose AI Agent Tracks Drug Project ProgressRohan Paul · 27 days ago
- OpenAI Acquires Drug Discovery Collaboration Platform Orchestra BioOpenAI · 27 days ago
Source: OpenAI: Official Website Updates · openai.com